PHVS — Pharvaris N.V.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1830487 ·
Netherlands
Last close
$32.28
Market Cap
$2.27B
52W High
$43.25
52W Low
$23.15
ADV30
591,343
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -50,082,251 | -47,412,993 | 295,063,721 | 282,732,818 | 30,089,488 |
| Jun 2026 | 0 | — | -50,788,287 | -47,842,729 | 328,667,391 | 318,282,453 | 27,856,887 |
| Mar 2026 | 0 | — | -44,272,001 | -39,200,673 | 259,788,041 | 246,957,998 | 23,455,647 |
| Dec 2025 | 0 | — | -47,599,025 | -46,740,853 | 301,454,999 | 291,678,888 | 30,180,665 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-155,188,603
Investing CF
$-99,256
Financing CF
$266,518,068
CapEx
$-99,256
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.73
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-668,576,894
Inventory
—
Receivables
$5,270,003
ST Investments
—
EBIT TTM
$-182,323,812
Pretax Income TTM
$-168,563,531
Interest Exp TTM
—
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -169,822,932 | -175,699,397 | 301,454,999 | 30,180,665 | 271,274,334 | -137,073,634 |
| Dec 2024 | 0 | -145,688,167 | -134,221,527 | 291,374,765 | 23,614,024 | 267,760,741 | -120,130,191 |
| Dec 2023 | 0 | -96,913,620 | -100,875,068 | 398,694,465 | 14,646,062 | 384,048,403 | -93,049,093 |
| Dec 2022 | 0 | -86,714,608 | -76,332,557 | 167,732,983 | 18,473,953 | 149,259,030 | -67,162,634 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.15
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $30.00 · spot: $31.55 · call volume: 68 · put volume: 66Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LKFT | Lakefront Biotherapeutics NV | $2.25B | $34.39 | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.29B | $48.22 | — |
| GLPGF | Lakefront Biotherapeutics NV | $2.30B | $35.15 | — |
| GRFS | Grifols SA | $2.23B | $8.63 | — |
| NAMS | NewAmsterdam Pharma Co N.V. | $2.33B | $19.39 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts See a 79.41% Upside in Pharvaris (PHVS): Can the Stock Really Move This High?
2026-11-16 13:55 · Yahoo
Pharvaris Presents Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
2026-11-12 15:28 · Yahoo
Pharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-12 11:50 · Yahoo
Pharvaris (PHVS) Stock Could Look Pricey Following Phase 3 Momentum
2026-11-04 15:11 · Yahoo
Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting
2026-10-29 10:50 · Yahoo
Bank of America backs Pharvaris on breakthrough for rare swelling disease
2026-10-26 23:00 · Yahoo
Phase 3 Study Results Highlighting Deucrictibant’s Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet
2026-10-08 22:35 · Yahoo
Could Real-World HAE Oral Preference Data Be a Pivotal Signal for Pharvaris' (PHVS) Strategy?
2026-10-08 15:10 · Yahoo
Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy
2026-10-05 10:50 · Yahoo
What Does Pharvaris (PHVS) Phase 3 HAE Success Mean Now?
2026-09-19 15:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.